ClinicalTrials.gg
RecruitingNCT05404321TRIPLEXUpdated Nov 20, 2026

Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment

An observational study in Triple Negative Breast Cancer and Organoid, sponsored by Centre Francois Baclesse. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Centre Francois Baclesse · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Nov 20, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
163
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Triple Negative Breast Neoplasms with a site in France — 35 open to participants now, 66 under way, 13 of them phase 3. Triple Negative Breast Neoplasms · France.

Started
2023
with 4 others
Observational
6 of 125
2 open now
Primary completion
2028-06
later than 38 of 65 live
Registered
82nd of 125
by date

Among the 125 studies in Triple Negative Breast Neoplasms with a site in France, this one is one of 5 that started in 2023, is one of 6 observational ones, reaches primary completion later than 38 of the 65 other live ones, and was the 82nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 125 studies in Triple Negative Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Triple Negative Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

Initially described in 2009 on LGR5 positive stem cells from intestine, organoids correspond to a 3D cell culture that preserves the organization and part of the initial function of the organ from which the cells were derived. They use the proliferation and differentiation properties of stem cells cultured in a three-dimensional matrix.

These principles have been adapted to many human organs, including the breast. These culture conditions have thus allowed the establishment of cancer organoid lines that have the advantages of rapid amplification, a high rate of establishment success and unlimited proliferation potential. They are transfectable and cryopreservable. They are very close morphologically and genetically to the tumor from which they derive. Very recently, the in vivo response of orthotopic xenograft models of breast cancer organoids has been correlated to the in vitro response of these same organoids. In addition, the in vitro response of various of these models to PARP inhibitors was linked to the presence of the BRCA1/2 mutant signature, highlighting the potential of these models to predict patient response to these treatments.

Furthermore, one study demonstrated the value of using organoids derived from metastatic gastrointestinal tumors to predict patient response to cancer treatments (100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value.

03

Conditions studied

  • Triple Negative Breast Cancer
  • Organoid
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age
  • A patient with early-stage (I-III) triple-negative breast cancer at the time of signing the form who is scheduled to undergo clip placement prior to chemotherapy or who agrees to undergo a new if a clip has already been placed
  • Patient affiliated to a social security system
  • Proficiency in French language,
  • Patient having signed the consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Persons deprived of liberty or under guardianship (including curatorship)
  • History of any other clinically active in the last 5 years prior to inclusion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
163 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient with early stage triple negative breast cancer

    Other: Establishment of ex vivo breast cancer organoid models

Interventions

  • OtherEstablishment of ex vivo breast cancer organoid models

    This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response

06

What researchers measure

Primary outcomes

  1. Rate of establishment of exploitable organoids tumor

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
  • Centre François Baclesse
    Caen, 14076, France
    Recruiting
    • George EMILE, MD · Contactg.emile@baclesse.unicancer.fr · +33 2 31 45 50 50
    • George EMILE, MD · Principal investigator
    • Christelle LEVY, MD · Sub investigator
    • Djelila ALLOUACHE, MD · Sub investigator
    • Audrey FAVEYRIAL, MD · Sub investigator
    • Ioana HRAB, MD · Sub investigator
    • Carine SEGURA, MD · Sub investigator
    • Alison JOHNSON, MD · Sub investigator
    • Adeline MOREL, MD · Sub investigator
    • Julien GEFFRELOT, MD · Sub investigator
08

References and documents

Publications

  • Divoux J, Florent R, Jacobs M, Lequesne J, Grellard JM, San C, Grossi S, Kerdja K, Clarisse B, Boudier G, Cherifi F, Briand M, Dolivet E, Johnson A, Dubois B, Harter V, Lacroix J, Raboutet C, Marie B, Rousseau N, Blanc-Fournier C, Vaur D, Figeac M, Poulain L, Weiswald LB, Emile G. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer. BMC Cancer. 2023 Sep 19;23(1):883. doi: 10.1186/s12885-023-11362-8. PubMed 37726786 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jun 2028, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 3, 2022
StartActual
Jan 9, 2023
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapyNow A patient with early-stage (I-III) triple-negative breast cancer at the time of signing the informed consent form who is scheduled to undergo clip placement prior to neoadjuvant chemotherapy or who agrees to undergo a new biopsy if a clip has already been placed
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapyNow A patient with early-stage (I-III) triple-negative breast cancer at the time of signing the informed consent form who is scheduled to undergo clip placement prior to neoadjuvant chemotherapy or who agrees to undergo a new biopsy if a clip has already been placed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05404321
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Jan 9, 2023
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

George EMILE, MD
Contact
g.emile@baclesse.unicancer.fr
+33 2 31 45 50 50

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion